###begin article-title 0
Science Review: Vasopressin and the cardiovascular system part 1 - receptor physiology
###end article-title 0
###begin p 1
###xml 379 381 379 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 392 394 392 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 402 404 402 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 447 449 447 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Vasopressin is emerging as a rational therapy for vasodilatory shock states. Unlike other vasoconstrictor agents, vasopressin also has vasodilatory properties. The goal of the present review is to explore the vascular actions of vasopressin. In part 1 of the review we discuss structure, signaling pathways, and tissue distributions of the classic vasopressin receptors, namely V1 vascular, V2 renal, V3 pituitary and oxytocin receptors, and the P2 class of purinoreceptors. Knowledge of the function and distribution of vasopressin receptors is key to understanding the seemingly contradictory actions of vasopressin on the vascular system. In part 2 of the review we discuss the effects of vasopressin on vascular smooth muscle and the heart, and we summarize clinical studies of vasopressin in shock states.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Arginine vasopressin (hereafter referred to as vasopressin), also known as antidiuretic hormone, is essential for survival, as attested by its teleologic persistence. Oxytocin- and vasopressin-like peptides have been isolated from four invertebrate phyla and the seven major vertebrate families, representing more than 120 species [1]. Therefore, the ancestral gene encoding the precursor protein appears to antedate the divergence of the vertebrate and invertebrate families, about 700 million years ago [2]. Virtually all vertebrate species possess an oxytocin-like and a vasopressin-like peptide, and so two evolutionary lineages can be traced. The presence of a single peptide, vasotocin ([Ile3]-vasopressin or [Arg8]-oxytocin), in the most primitive cyclostomata supports the notion that primordial gene duplication with subsequent mutations gave rise to the two lineages [2].
###end p 3
###begin p 4
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 472 473 472 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Vasopressin is essential for cardiovascular homeostasis. The vasopressor effect of pituitary extract, first observed in 1895, was attributed to the posterior lobe of this gland [3]. It was not until 18 years later that the antidiuretic effect of neurohypophyseal extract was demonstrated [4,5]. After isolation and synthesis of vasopressin in the 1950s, it was proven that the same hormone in the posterior pituitary possessed both antidiuretic and vasopressor effects [6,7]. The importance of vasopressin in osmotic defense is fundamental. Indeed, the antidiuretic effect of vasopressin has been exploited clinically for over half a century to treat diabetes insipidus. Only recently has vasopressin emerged as a therapy for shock states, renewing interest in the cardiovascular effects of vasopressin.
###end p 4
###begin p 5
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Shock states induce an increase in vasopressin levels from 20- to 200-fold [8-12]. These supraphysiologic levels cause profound vasoconstriction and help to maintain end-organ perfusion [13,14]. Prolonged shock is associated with a fall in vasopressin levels [15-18], probably due to depletion of vasopressin stores [19,20], and may contribute to the refractory hypotension that is seen in advanced shock states. Paradoxically, vasopressin has also been demonstrated to cause vasodilation in some vascular beds [21-28], distinguishing this hormone from other vasoconstrictor agents.
###end p 5
###begin p 6
The present review explores the vascular actions of vasopressin. First, a discussion of the signaling pathways and distribution of vasopressin receptors is necessary to gain an understanding of the seemingly paradoxic vasodilatory and vasoconstrictor actions of vasopressin. We discuss the structural elements responsible for the functional diversity found within the vasopressin receptor family. In part 2 of our review, we explore the mechanisms of vasoconstriction and vasodilation of the vascular smooth muscle, with an emphasis on vasopressin interaction in these pathways. We review the seemingly contradictory studies and some new information regarding the actions of vasopressin on the heart. Finally, we summarize the clinical trials of vasopressin in vasodilatory shock states and comment on areas for future research.
###end p 6
###begin title 7
Overview of vasopressin
###end title 7
###begin title 8
Structure of the hormone and the genes
###end title 8
###begin p 9
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Vasopressin is a nonapeptide with a disulfide bridge between two cysteine amino acids [29] and is synthesized by the magnocellular neurons of the hypothalamus [30] (Fig. 1). Although oxytocin differs from vasopressin by only one amino acid (80% homology), they have clearly divergent physiologic activity. Vasopressin is involved in osmotic and cardiovascular homeostasis, whereas oxytocin is important in parturition, lactation, and sexual behavior.
###end p 9
###begin p 10
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
Oxytocin and vasopressin are encoded by separate genes but they lie on the same chromosome, at 20p [31], separated by a segment of DNA only 12 kilobases long [32]. The similarities in structure as well as the close apposition are suggestive of recent gene duplication [33]. Despite ample documentation of cell-specific expression and physiologic regulation of the vasopressin gene, there is striking lack of progress in identifying transcription factors that act on the vasopressin promoter [34].
###end p 10
###begin title 11
Structure of the receptor
###end title 11
###begin p 12
###xml 148 150 148 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 161 162 161 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 177 178 177 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 183 185 183 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 197 198 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 239 241 239 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 264 265 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 497 498 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 501 503 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 938 940 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1138 1139 1131 1132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 1154 1155 1143 1144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1188 1190 1177 1179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q </sub>
###xml 1195 1197 1184 1186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">11</sub>
###xml 1306 1308 1295 1297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 1375 1377 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
The actions of vasopressin are mediated by stimulation of tissue-specific G-protein-coupled receptors (GPCRs), which are currently classified into V1 vascular (V1R), V2 renal (V2R), V3 pituitary (V3R) and oxytocin (OTR) subtypes [35] and P2 purinergic receptors (P2R) [36]. The GPCRs are comprised of seven hydrophobic transmembrane alpha-helices joined by alternating intracellular and extracellular loops, an extracellular amino-terminal domain, and a cytoplasmic carboxyl-terminal domain (Fig. 2) [29]. The actions of vasopressin are signaled through pathways that are similar to extracellular agents such as hormones (glucagon, luteinizing hormone, and epinephrine [adrenaline]), neurotransmitters (acetylcholine, dopamine, and serotonin) and chemokines (interleukin-8). Local mediators signal to the four main G protein families to regulate cellular machinery such as metabolic enzymes, ion channels, and transcriptional regulators [37]. The extracellular signals are routed to specific G proteins through distinct types of receptors. For example, epinephrine's signal is transmitted through the beta-adrenergic receptor coupled to Gi, and the alpha1-adrenergic receptor coupled to Gq and G11. Many important hormones, including epinephrine, acetylcholine, dopamine, and serotonin, interact with the Gi pathway, which is characterized by inhibition of adenylyl cyclase [37].
###end p 12
###begin p 13
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 512 513 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s</sub>
###xml 516 519 516 519 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i/o</sub>
###xml 522 526 522 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11</sub>
###xml 533 539 533 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12/13 </sub>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Agonist stimulation of vasopressin receptors leads to receptor subtype-specific interactions with G-protein-coupled receptor kinases (GRKs) and protein kinase C (PKC) through specific motifs that are present in the carboxyl termini of the receptors [38]. Guanine nucleotide-binding proteins (G-proteins) are signal transducers, attached to the cell surface membrane, that connect receptors to effectors and thus to intracellular signaling pathways [39]. Functional characterization of the G-proteins, including Gs, Gi/o, Gq/11, and G12/13 [37], indicates that a single receptor can activate multiple second messenger pathways through interaction with one or more G-proteins [40-42].
###end p 13
###begin p 14
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 57 62 57 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 82 84 82 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 370 372 367 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 396 401 393 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 606 608 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 769 771 759 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q </sub>
###xml 834 836 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
Vasopressin's signal is transmitted through both Gs and Gq/11 subtypes [37]. The Gs pathway is characterized by inhibition of adenylyl cyclase, leading to increased levels of cAMP that in turn connects to multiple cellular machines, including ion channels, transcription factors, and metabolic enzymes. Both beta-adrenergic receptors and vasopressin receptors regulate Gs protein signaling. The Gq/11 pathway is the classical pathway that is activated by calcium-mobilizing hormones and stimulates phospholipase-beta to produce the intracellular messengers inositol trisphosphate and diacylglycerol (DAG) [37]. Inositol trisphosphate triggers the release of calcium from intracellular stores and DAG recruits PKC to the membrane and activates it. The alpha-subunit of Gq also activates the transcription factor nuclear factor-kappaB [43].
###end p 14
###begin title 15
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The V1 receptor
###end title 15
###begin p 16
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 126 131 126 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 221 223 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 282 283 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 358 359 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 399 401 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
The V1R gene is located on chromosome 12 and maps to region 12q14-15 [44]. Functionally, the V1R activates G-proteins of the Gq/11 family. The alpha-subunits regulate the activity of the beta-isoforms of phospholipase C [29]. A variety of signaling pathways is associated with the V1R, and these pathways include activation of calcium influx, phospholipase A2, phospholipase C, and phospholipase D [45].
###end p 16
###begin p 17
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 213 214 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 274 275 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
V1Rs are found in high density on vascular smooth muscle and cause vasoconstriction by an increase in intracellular calcium via the phosphatidyl-inositol-bisphosphonate cascade. Cardiac myocytes also possess the V1R and are discussed in part 2 of the review. Additionally, V1Rs are located in brain, testis, superior cervical ganglion, liver, blood vessels, and renal medulla [46]. The exact physiologic role of vasopressin in many of these diverse tissues remains unknown.
###end p 17
###begin p 18
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 535 536 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 216 221 <span type="species:ncbi:9606">human</span>
###xml 420 425 <span type="species:ncbi:9606">human</span>
Platelets express the V1R, which upon stimulation induces an increase in intracellular calcium, facilitating thrombosis [47]. However, there appears to be tremendous variability in the aggregation response of normal human platelets to vasopressin [48]. Based on kinetic studies and the effects of PKC inhibition on the aggregation response to vasopressin, significant heterogeneity in the aggregation response of normal human platelets to vasopressin has been demonstrated, which is probably related to a polymorphism of the platelet V1R [49].
###end p 18
###begin p 19
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 209 210 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 303 304 303 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 380 383 380 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1a </sub>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 528 529 528 529 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 594 595 594 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 826 827 826 827 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1099 1107 <span type="species:ncbi:9606">patients</span>
V1Rs are found in the kidney, where they occur in high density on medullary interstitial cells, vasa recta, and epi thelial cells of the collecting duct. Vasopressin acts on medullary vasculature through the V1R to reduce blood flow to inner medulla without affecting blood flow to outer medulla [50]. V1Rs on the luminal membrane of the collecting duct probably exerted through V1a receptors located on luminal membrane limit the antidiuretic effects of vasopressin [50]. Interestingly, cyclosporine A induces upregulation of V1R mRNA in vascular smooth muscle [51], increasing the number of V1Rs by twofold [52], which could be a key mechanism by which cyclosporine A causes both hypertension and reduced glomerular filtration. Additionally, vasopressin selectively contracts efferent arterioles [53], probably through the V1R, but not the afferent arteriole. This selectivity, which is not shared by catecholamine vasopressors, would tend to increase glomerular filtration, probably accounting for the paradoxic increase in urine output observed when this antidiuretic hormone is administered to patients in vasodilatory shock [54,55].
###end p 19
###begin p 20
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 132 133 132 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 80 83 <span type="species:ncbi:10116">rat</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 167 170 <span type="species:ncbi:10116">rat</span>
There is considerable interspecies variation in the V1R. For instance, although rat and human vasopressin are identical, the human V1R is only 80% homologous with the rat V1R [1]. This must be kept in mind when interpreting animal studies aimed at interpreting receptor subtypes based on the use of specific receptor inhibitors.
###end p 20
###begin title 21
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The V2 receptor
###end title 21
###begin p 22
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 107 108 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 191 192 191 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 292 293 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 369 370 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 377 378 377 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 474 476 474 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 486 488 486 488 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 529 530 529 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 533 535 533 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 682 683 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 736 741 736 741 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
The V2 R differs from the V1R primarily in the number of sites susceptible to N-linked glycosylation; the V1R has sites at both the amino-terminus and at the extracellular loop, whereas the V2R has a single site at the extracellular amino-terminus [56]. Despite structural similarities, the V2R differs functionally from the V1R. Mutagenesis experiments involving the V1R and V2R have confirmed that the short sequence at the amino-terminus of the cytoplasmic tail confers V2 receptor-Gs coupling selectivity. The efficiency of V2R-Gs coupling can be modulated by the length of the central portion of the third intracellular loop [57], whereas the second intracellular loop of the V1R is critically involved in selective activation of Gq/11 [58].
###end p 22
###begin p 23
###xml 80 81 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 802 803 802 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 907 908 905 906 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 937 939 935 937 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1012 1014 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
The well known antidiuretic effect of vasopressin occurs via activation of the V2R. Vasopressin regulates water excretion from the kidney by increasing the osmotic water permeability of the renal collecting duct - an effect that is explained by coupling of the V2R with the Gs signaling pathway, which activates cAMP [59]. The increased intracellular cAMP in the kidney [60,61] in turn triggers fusion of aquaporin-2-bearing vesicles with the apical plasma membrane of the collecting duct principal cells, increasing water reabsorption [62]. Vasopressin regulates water homeostasis in two ways: regulation of the fast shuttling of aquaporin 2 to the cell surface and stimulation of the synthesis of mRNA encoding aquaporin 2 [63]. Most cases of diabetes insipidus can be explained by mutations in the V2R gene, which is located on chromosome region 10q28 [64]. For example, an Arg137-->His mutation in the V2R abolishes coupling to the Gs protein, causing a complete phenotype of nephrogenic diabetes insipidus [65].
###end p 23
###begin p 24
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 430 431 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 482 483 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 490 491 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 511 520 511 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 557 558 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 565 566 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 942 943 942 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
It has been postulated that the V2R is also expressed in endothelium because the potent V2R agonist 1-deamino-8-D-arginine vasopressin (DDAVP) causes both release of von Willebrand factor and vasodilation [21]. Previous studies of the localization and distribution of different vasopressin receptors have been hampered by the use of nonselective radioligands such as [3H]arginine vasopressin, which binds to all types of V1R and V2R, certain OTRs, and neurophysins. When selective V1R and V2R radioligands with in vitro auto-radiography were used to study V1R and V2R binding sites, no binding was demonstrated on endothelium or liver, where DDAVP might influence clotting factor release, or in the brain, spinal cord, sympathetic ganglia, heart or vascular smooth muscle - regions where DDAVP might cause vasodilation [46]. Specific binding was only identified in the kidney, which is consistent with the known distribution of antidiuretic V2Rs on renal collecting tubules.
###end p 24
###begin title 25
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
The V3 receptor
###end title 25
###begin p 26
###xml 11 12 11 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 36 38 36 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1b</sub>
###xml 152 153 152 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 282 283 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 287 288 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 333 334 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 543 544 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 395 400 <span type="species:ncbi:9606">human</span>
The human V3R (previously known as V1bR) is a G-protein-coupled pituitary receptor that, because of its scarcity, was only recently characterized. The V3R gene maps to chromosome region 1q32 [66]. The 424-amino-acid sequence of the V3R has homologies of 45%, 39%, and 45% with the V1R, V2R, and OTR, respectively [67]. However, the V3R has a pharmacologic profile that distinguishes it from the human V1R and activates several signaling pathways via different G-proteins, depending on the level of receptor expression [68]. Interestingly the V3R is also is over-expressed in adrenocorticotropic hormone (ACTH)-hypersecreting tumors.
###end p 26
###begin p 27
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 336 341 336 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 580 581 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s</sub>
###xml 584 585 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 592 597 592 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 608 609 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 784 785 784 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 796 797 796 797 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
More than one G-protein appears to participate in signal transduction pathways linked to V3Rs, depending on the level of receptor expression and the concentration of vasopressin [69]. For instance, vasopressin causes secretion of ACTH from the anterior pituitary cells in a dose-dependent manner through activation of PKC [70] via the Gq/11 class [68]. Other cellular responses, including increased synthesis of DNA and cAMP, which are important in the induction and phenotype maintenance of ACTH-secreting tumors, are mediated through recruitment of several pathways, including Gs, Gi, and Gq/11 [68]. The V3R has been inferred to exist in the pancreas [71] on the basis of antagonist studies; however, this conclusion may be suspect because significant homology exists between the V3R and the V1R [59].
###end p 27
###begin title 28
The oxytocin receptor
###end title 28
###begin p 29
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 242 247 242 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">q/11 </sub>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
The OTR can be considered a 'nonselective' vasopressin receptor. The OTR has equal affinity for vasopressin and oxytocin, whereas the V1R has a 30-fold higher affinity for vasopressin than for oxytocin [72]. OTRs are functionally coupled to Gq/11 class binding proteins, which stimulate the activity of phospholipase C [73]. This leads to the generation of inositol trisphosphate and 1,2-DAG. Inositol trisphosphate triggers calcium release from intracellular stores, whereas DAG stimulates PKC, which phosphorylates unidentified target proteins [73]. A variety of cellular events are initiated in response to an increase in intracellular calcium. For example, the forming calcium-calmodulin complexes trigger activation of neuronal and endothelial isoforms of nitric oxide synthase. Nitric oxide in turn stimulates the soluble guanylate cyclase to produce cGMP, leading to vasodilation. In smooth muscle cells, the calcium-calmodulin system triggers the activation of myosin light chain kinase activity, which initiates smooth muscle contraction (e.g. in myometrial or mammary myoepithelial cells) [74]. In neurosecretory cells, rising calcium levels control cellular excitability, modulate their firing patterns, and lead to transmitter release. Further calcium-promoted processes include gene transcription and protein synthesis.
###end p 29
###begin p 30
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
OTRs have been localized to a variety of reproductive and nonreproductive tissues [73]. Importantly, OTRs exist in high density on vascular endothelium, mediating nitric oxide dependent vasodilation [75]. Recently, the oxytocin/OTR system has been discovered in the heart. Activation of cardiac OTR stimulates the release of atrial natriuretic peptide, which is involved in natriuresis, regulation of blood pressure, and cell growth [76]. Embryonic stem cells exposed to oxytocin exhibit increased atrial natriuretic peptide mRNA and abundant mitochondria, and express sarcomeric myosin heavy chain, which is consistent with promotion of cardiomyocyte differentiation [77].
###end p 30
###begin title 31
Purinergic receptors
###end title 31
###begin p 32
###xml 54 56 54 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 227 228 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 307 314 307 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#947; </sub>
###xml 319 322 315 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2&#957;</sub>
###xml 463 465 458 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 634 636 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
Recently, vasopressin was demonstrated to act on the P2 class of purinoreceptors (P2Rs) [36]. P2Rs also belong to the seven-transmembrane-domain GPCR superfamily. ATP released from platelets and damaged cells bind endothelial P2Rs [78]. ATP can act on either of the two subclasses of purinoceptors, namely P2gamma and P2nu. In both cases, activation of phospholipase C leads to mobilization of intracellular calcium stores. This binding stimulates phospholipase A2 and nitric oxide synthase, resulting in increased synthesis and release of prostacyclin and nitric oxide, respectively, and causing vascular smooth muscle vasodilation [78].
###end p 32
###begin p 33
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 438 440 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 568 569 562 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 704 706 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
Purinoreceptors may also have an important role in cardiac contractility. ATP released by platelets, endothelial cells, and damaged myocardium activates the P2R, causing a large increase in cytosolic calcium and myocyte contractile amplitude [79]. ATP is also released as a cotransmitter with norepinephrine from sympathetic nerve endings and acts in a synergistic manner with beta-adrenergic agents, increasing myocardial contractility [80]. In contrast to beta-adrenergic agents, inotropy is not accompanied by a positive chronotropic effect. It is speculated that P2R agonist-stimulated increase in contractility could occur without the expense of a rate-related increase in myocardial oxygen demand [79].
###end p 33
###begin p 34
###xml 80 81 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 409 410 409 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 505 506 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 799 800 799 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 877 878 877 878 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 276 286 <span type="species:ncbi:10141">guinea pig</span>
###xml 630 633 <span type="species:ncbi:10116">rat</span>
###xml 820 825 <span type="species:ncbi:9606">human</span>
Recently, vasopressin was shown to exert cardiac effects through activation of P2Rs expressed on cardiac endothelium. Intracoronary infusion of vasopressin-dextran (confines vasopressin to the intravascular space) and vasopressin at maximal concentration in isolated perfused guinea pig hearts caused coronary vasoconstriction and negative inotropy-effects that were blocked with vasopressin antagonists and P2R antagonist [36]. Caution must be exercised in interpreting this study because activation of P2Rs and increased levels of ATP normally increase inotropy. Furthermore, the same experiments performed in isolated perfused rat hearts demonstrated positive inotropy - an effect that was blocked by P2R antagonists [36]. Further study is necessary to ascertain the significance of vasopressin P2R activation in the human heart, but the discovery that vasopressin acts on P2Rs is intriguing.
###end p 34
###begin p 35
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 291 292 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 328 331 328 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2b </sub>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
A number of pharmacologic observations have suggested the existence of vasopressin receptor/OTR subtypes beyond the five described above [72]. These include receptors for the metabolites of vasopressin and oxytocin (VP4-9 R and OT4-9 R) [72], and a cAMP-coupled vasopressin receptor with a V1-like pharmacologic profile termed V2b [81]. A novel 'vasotocin-like' receptor subtype has also been proposed [82].
###end p 35
###begin title 36
Vasopressin/oxytocin receptor downregulation
###end title 36
###begin p 37
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 418 420 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 421 423 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 632 634 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
Upon ligand binding, GPCRs undergo activation followed by a decrease in receptor responsiveness (desensitization). Agonist-dependent desensitization of these receptors can reduce their signaling responsiveness to maximum stimulation by up to 70-80% [83]. Receptor desensitization occurs when activated receptors become phosphorylated and bind to beta-arrestin proteins, inhibiting further interaction with G-proteins [84,85]. Receptor responsiveness is also limited by the degradation of cAMP by phosphodiesterases. beta-Arrestins coordinate both phosphorylation of receptors and the rate of cAMP degradation by phosphodiesterases [85].
###end p 37
###begin p 38
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 225 226 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 237 238 234 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 318 319 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 355 357 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 572 574 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 575 577 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 678 683 <span type="species:ncbi:9606">human</span>
Exposure to vasopressin leads to desensitization of the V1R, which occurs quickly and is accompanied by sequestration of receptors inside the cell [59]. The V1R can also be desensitized by angiotensin II [86]. Compared with V1Rs and beta2-adrenergic receptors, which are known to recycle and resensitize rapidly, the V2R recycles and resensitizes slowly [87]. Mutagenesis experiments demonstrate that the interaction of beta-arrestin with a specific motif in the GPCR carboxyl-terminal tail dictates the rate of receptor dephosphorylation, recycling, and resensitization [87,88]. The clinical importance of vasopressin desensitization of the vasopressin receptor/ OTR family in human disease states is currently unknown.
###end p 38
###begin p 39
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
Despite the clinical importance of the vasopressin receptors and OTRs, little is known about the mechanisms by which they undergo internalization and desensitization. Agonist activation of all vasopressin receptor/OTR subtypes leads to a specific physical association of the receptors with GRKs and/or PKC, following different time courses that are specific to the receptor subtype [38]. The pattern of interaction with GRKs and PKC is also unique to each vasopressin receptor subtype and occurs at the level of their carboxyl-termini [38].
###end p 39
###begin p 40
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 190 191 187 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 294 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 328 330 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 337 338 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 392 393 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 587 589 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 864 866 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 963 969 <span type="species:ncbi:9606">humans</span>
Vasopressin is known to modulate the effect of other vasoactive agents [89,90] - an interaction that may be explained by arrestin trafficking. Isoproterenol-dependent internalization of beta2-adrenergic receptors is specifically blocked (>65% inhibition) by vasopressin-induced activation of V2Rs coexpressed at similar levels [42]. beta2-Adrenergic receptors caused no detectable effect on V2R internalization in the same cells. There is evidence to suggest that this nonreciprocal inhibition of endocytosis is mediated by receptor-specific intracellular trafficking of beta-arrestins [42]. Interestingly, interaction of vasopressin with arrestins and resistance of vasopressin receptors to downregulation may explain the reported ability of vasopressin to bypass desensitized myocardial adrenergic receptors in an experimental model of congestive heart failure [91]. The clinical importance of vasopressin upregulation of adrenergic receptors in critically ill humans is an important area for further study.
###end p 40
###begin title 41
Conclusion
###end title 41
###begin p 42
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
During the past 10 years, considerable progress has been made in our understanding of vasopressin receptor structure and function. The physiologic significance of the various receptors has been elucidated by the development of specific agonists and antagonists, particularly by Dr Maurice Manning's group [92-94]. An understanding of the molecular basis of receptor function will greatly aid in the development of new molecules with high selectivity for the different subtypes of receptors, and will have potential therapeutic significance, not only for conditions as diverse as hypertension, diabetes insipidus and premature labor, but also in vasodilatory shock with organ dysfunction. In part 2 of the review, we discuss the interaction of vasopressin with its various receptors in vascular smooth muscle and the heart, and its potential utility in vasodilatory shock states.
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
None declared.
###end p 44
###begin title 45
Abbreviations
###end title 45
###begin p 46
###xml 228 229 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 234 236 234 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 265 267 265 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 287 288 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 293 295 293 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 318 320 318 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
ACTH = adrenocorticotropic hormone; DAG = diacylglycerol; DDAVP = 1-deamino-8-D-arginine vasopressin; GPCR = G-protein-coupled receptor; GRK = G protein-coupled receptor kinase; OTR = oxytocin receptor; PKC = protein kinase C; P2R = P2 purinergic receptors; V1R = V1 vascular receptor; V2R = V2 renal receptor; V3R = V3 pituitary receptor.
###end p 46
###begin article-title 47
Neuropeptide families and their receptors: evolutionary perspectives
###end article-title 47
###begin article-title 48
###xml 0 3 <span type="species:ncbi:9606">Man</span>
Man and the chimaera. Selective versus neutral oxytocin evolution
###end article-title 48
###begin article-title 49
On the physiological action of extracts of the pituitary body and certain other glandular organs
###end article-title 49
###begin article-title 50
###xml 44 50 <span type="species:ncbi:9606">humans</span>
The renal effects of hypophyseal extract in humans [in German]
###end article-title 50
###begin article-title 51
The antidiuretic hormone and the factor which determines its release
###end article-title 51
###begin article-title 52
The purification and the amino acid content of vasopressin preparation
###end article-title 52
###begin article-title 53
A synthetic preparation possessing biological properties associated with argininevasopressin
###end article-title 53
###begin article-title 54
###xml 127 141 127 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Macaca mulatta</italic>
###xml 127 141 <span type="species:ncbi:9544">Macaca mulatta</span>
The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta)
###end article-title 54
###begin article-title 55
###xml 87 90 <span type="species:ncbi:9615">dog</span>
Evidence and quantification of the vasopressin arterial pressure control system in the dog
###end article-title 55
###begin article-title 56
###xml 54 61 <span type="species:ncbi:9557">baboons</span>
###xml 66 70 <span type="species:ncbi:9615">dogs</span>
Vasopressin release during sepsis and septic shock in baboons and dogs
###end article-title 56
###begin article-title 57
Release of vasoactive hormones and circulatory changes in shock
###end article-title 57
###begin article-title 58
Ventricular receptors stimulate vasopressin release during hemorrhage
###end article-title 58
###begin article-title 59
###xml 91 95 <span type="species:ncbi:9615">dogs</span>
Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs
###end article-title 59
###begin article-title 60
Role of vasopressin in cardiovascular and blood pressure regulation
###end article-title 60
###begin article-title 61
The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock
###end article-title 61
###begin article-title 62
Vasopressin pressor hypersensitivity in vasodilatory septic shock
###end article-title 62
###begin article-title 63
Vasopressin deficiency contributes to the vasodilation of septic shock
###end article-title 63
###begin article-title 64
Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock
###end article-title 64
###begin article-title 65
The pathogenesis of vasodilatory shock
###end article-title 65
###begin article-title 66
Depletion of neurohypophyseal content of vasopressin in septic shock
###end article-title 66
###begin article-title 67
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus
###end article-title 67
###begin article-title 68
###xml 46 50 <span type="species:ncbi:10116">rats</span>
Vasopressin-induced pulmonary vasodilation in rats
###end article-title 68
###begin article-title 69
Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide
###end article-title 69
###begin article-title 70
Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo
###end article-title 70
###begin article-title 71
Arginine vasopressin-induced renal vasodilation mediated by nitric oxide
###end article-title 71
###begin article-title 72
Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles
###end article-title 72
###begin article-title 73
Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries
###end article-title 73
###begin article-title 74
Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries
###end article-title 74
###begin article-title 75
Structural bases of vasopressin/oxytocin receptor function
###end article-title 75
###begin article-title 76
###xml 48 51 <span type="species:ncbi:10116">rat</span>
Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus
###end article-title 76
###begin article-title 77
###xml 26 31 <span type="species:ncbi:9606">human</span>
Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor
###end article-title 77
###begin article-title 78
###xml 25 30 <span type="species:ncbi:9606">human</span>
Linkage relationships of human arginine vasopressin-neurophysin-II and oxytocin-neurophysin-I to prodynorphin and other loci on chromosome 20
###end article-title 78
###begin article-title 79
###xml 33 39 <span type="species:ncbi:9913">bovine</span>
Recent gene conversion involving bovine vasopressin and oxytocin precursor genes suggested by nucleotide sequence
###end article-title 79
###begin article-title 80
Regulation of gene promoters of hypothalamic peptides
###end article-title 80
###begin article-title 81
###xml 26 31 <span type="species:ncbi:9606">human</span>
Molecular pharmacology of human vasopressin receptors
###end article-title 81
###begin article-title 82
Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors
###end article-title 82
###begin article-title 83
G protein pathways
###end article-title 83
###begin article-title 84
###xml 23 28 <span type="species:ncbi:9606">human</span>
Dynamic interaction of human vasopressin/oxytocin receptor subtypes with g protein-coupled receptor kinases and protein kinase c after agonist stimulation
###end article-title 84
###begin article-title 85
Biochemical properties of hormone-sensitive adenylate cyclase
###end article-title 85
###begin article-title 86
Mutations and diseases of G protein coupled receptors
###end article-title 86
###begin article-title 87
Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density
###end article-title 87
###begin article-title 88
Heterologous inhibition of G protein-coupled receptor endocytosis mediated by receptor-specific trafficking of beta-arrestins
###end article-title 88
###begin article-title 89
PYK2 links G(q)alpha and G(13)alpha signaling to NF-kappa B activation
###end article-title 89
###begin article-title 90
###xml 69 74 <span type="species:ncbi:9606">human</span>
Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene
###end article-title 90
###begin article-title 91
The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels
###end article-title 91
###begin article-title 92
###xml 45 48 <span type="species:ncbi:10116">rat</span>
Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands
###end article-title 92
###begin article-title 93
Mechanism of vasopressin-induced platelet aggregation
###end article-title 93
###begin article-title 94
###xml 25 30 <span type="species:ncbi:9606">human</span>
Homologous regulation of human platelet vasopressin receptors does not occur in vivo
###end article-title 94
###begin article-title 95
###xml 45 50 <span type="species:ncbi:9606">human</span>
Heterogeneity of the aggregation response of human platelets to arginine vasopressin
###end article-title 95
###begin article-title 96
Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects
###end article-title 96
###begin article-title 97
Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment
###end article-title 97
###begin article-title 98
Mechanism of enhanced vasoconstrictor hormone action in vascular smooth muscle cells by cyclosporin A
###end article-title 98
###begin article-title 99
Renal microvascular effects of vasopressin and vasopressin antagonists
###end article-title 99
###begin article-title 100
The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series
###end article-title 100
###begin article-title 101
Vasopressin infusion in SIRS and septic shock: a randomized controlled trial
###end article-title 101
###begin article-title 102
A fully active nonglycosylated V2 vasopressin receptor
###end article-title 102
###begin article-title 103
Molecular basis of V2 vasopressin receptor/Gs coupling selectivity
###end article-title 103
###begin article-title 104
Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family
###end article-title 104
###begin article-title 105
Vasopressin receptors
###end article-title 105
###begin article-title 106
The role of adenosine 3',5'-phosphate in the action of antidiuretic hormone
###end article-title 106
###begin article-title 107
Role of cyclic AMP in the action of neurohypophyseal hormones on kidney
###end article-title 107
###begin article-title 108
###xml 104 107 <span type="species:ncbi:10116">rat</span>
Characterization of purified endosomes containing the antidiuretic hormone-sensitive water channel from rat renal papilla
###end article-title 108
###begin article-title 109
Regulation of aquaporin-2 water channel trafficking by vasopressin
###end article-title 109
###begin article-title 110
Localization of the gene for X-linked nephrogenic diabetes insipidus to Xq28
###end article-title 110
###begin article-title 111
Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase
###end article-title 111
###begin article-title 112
###xml 32 37 <span type="species:ncbi:9606">human</span>
Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32
###end article-title 112
###begin article-title 113
###xml 67 72 <span type="species:ncbi:9606">human</span>
Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor
###end article-title 113
###begin article-title 114
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways
###end article-title 114
###begin article-title 115
###xml 36 41 <span type="species:ncbi:9606">human</span>
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors
###end article-title 115
###begin article-title 116
Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion
###end article-title 116
###begin article-title 117
Effect of AVP and oxytocin on insulin release: involvement of V1b receptors
###end article-title 117
###begin article-title 118
Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family
###end article-title 118
###begin article-title 119
The oxytocin receptor system: structure, function, and regulation
###end article-title 119
###begin article-title 120
Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium
###end article-title 120
###begin article-title 121
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human vascular endothelial cells express oxytocin receptors
###end article-title 121
###begin article-title 122
Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart
###end article-title 122
###begin article-title 123
Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes
###end article-title 123
###begin article-title 124
G protein-coupled P2 purinoceptors: from molecular biology to functional responses
###end article-title 124
###begin article-title 125
###xml 77 80 <span type="species:ncbi:10116">rat</span>
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts
###end article-title 125
###begin article-title 126
Synergism between cAMP and ATP in signal transduction in cardiac myocytes
###end article-title 126
###begin article-title 127
Vasopressin-induction of cyclic AMP in cultured hippocampal neurons
###end article-title 127
###begin article-title 128
Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
###end article-title 128
###begin article-title 129
Desensitization of G protein-coupled receptors
###end article-title 129
###begin article-title 130
G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications
###end article-title 130
###begin article-title 131
Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins
###end article-title 131
###begin article-title 132
Protein kinase C modulation of cardiomyocyte angiotensin II and vasopressin receptor desensitization
###end article-title 132
###begin article-title 133
Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization
###end article-title 133
###begin article-title 134
Phosphorylation and recycling kinetics of G protein-coupled receptors
###end article-title 134
###begin article-title 135
Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins
###end article-title 135
###begin article-title 136
###xml 66 69 <span type="species:ncbi:10116">rat</span>
Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery
###end article-title 136
###begin article-title 137
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 92 95 <span type="species:ncbi:10116">rat</span>
Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes
###end article-title 137
###begin article-title 138
Functional architecture of vasopressin/oxytocin receptors
###end article-title 138
###begin article-title 139
Design of potent antagonists of the vasopressor response to argininevasopressin
###end article-title 139
###begin article-title 140
Discovery, development, and some uses of vasopressin and oxytocin antagonists
###end article-title 140
###begin article-title 141
Physiology of vasopressin relevant to management of septic shock
###end article-title 141
###begin article-title 142
Molecular pharmacology and modeling of vasopressin receptors
###end article-title 142
###begin title 143
Figures and Tables
###end title 143
###begin p 144
###xml 1243 1249 1243 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chest </italic>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
Hypothalamic nuclei involved in vasopressin control. The hypothalamus surrounds the third ventricle ventral to the hypothalamic sulci. The main hypothalamic nuclei subserving vasopressin control are the median preoptic nucleus (MNPO), the paraventricular nuclei (PVN), and the supraoptic nuclei (SON), which project to the posterior pituitary along the supraoptic-hypophyseal tract. Afferent nerve impulses from stretch receptors in the left atrium (inhibitory), aortic arch, and carotid sinuses (excitatory) travel via the vagus nerve, and neural pathways project to the PVN and the SON. These nuclei also receive osmotic input from the lamina terminalis, which is excluded from the blood-brain barrier and is thus affected by systemic osmolality. Vasopressin is synthesized in the cell bodies of the magnocellular neurons located in the PVN and SON. The magnocellular neurons of the SON are directly depolarized by hypertonic conditions (hence releasing more vasopressin) and hyperpolarized by hypotonic conditions (hence releasing less vasopressin). Finally, vasopressin migrates (in its prohormone state) along the supraoptic-hypophyseal tract to the posterior pituitary, where it is released into the circulation. Used by permission from Chest [95].
###end p 144
###begin p 145
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 497 559 497 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Molecular pharmacology and modeling of vasopressin receptors. </bold>
###xml 559 574 559 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prog Brain Res </italic>
###xml 580 583 580 583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">139</bold>
###xml 634 636 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
Vasopressin docking and transmembrane topology of the human V1 vascular receptor (V1R). A model of arginine vasopressin (AVP), as bound to the human V1R, is depicted. Vasopressin is shown in ball-and-stick representation and the receptor is shown in ribbons. The intracellular loops of the receptor are labeled il1, il2, and il3, and the extracellular loops are labeled el1, el2, and el3. The transmembrane segments are labeled H1-H7. Reprinted from Thibonnier M, Coles P, Thibonnier A, Shoham M: Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res 2002, 139:179-196. (c) 2002, with permission from Elsevier [96].
###end p 145

